November 7, 2012; Copenhagen, Denmark;
Interim Report for the 9 Months Ended September 30, 2012
“During the last nine months we have delivered on a great number of our objectives and made very significant progress towards becoming a sustainable company. The daratumumab collaboration with Janssen Biotech and the two recent DuoBody deals with Novartis and Janssen Biotech have not only increased our financial security, but also serve to build our future pipeline,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Financial Performance First Nine Months
Business Progress Third Quarter to Present
Genmab is improving its 2012 financial guidance due to higher Arzerra royalty income which is now expected to be in the range of DKK 105 – 115 million, an increase of DKK 15 million compared to the previous guidance of DKK 90 – 100 million.
Genmab will hold a conference call in English to discuss the results for the first nine months of 2012 today, Wednesday, November 7, at 6.00 pm CET, 5.00 pm GMT or noon EST. The dial in numbers are:
+1 718 354 1226 (US participants) and ask for the Genmab conference call
+44 207 509 5139 (international participants) and ask for the Genmab conference call
A live and archived webcast of the call and relevant slides will be available at www.genmab.com.
To read the full PDF version of the Interim Report for the 9 Months Ended September 30, 2012, visit Genmab’s website at http://ir.genmab.com/annuals.cfm.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company’s first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab’s validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: firstname.lastname@example.org
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody® and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.
Company Announcement no. 29
CVR no. 2102 3884
1260 Copenhagen K